Mercer Global Advisors
APLS

Mercer Global Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Mercer Global Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,663
Closed -$429K – 6104
2026
Q1 		$429K Sell
10,663
-7,005
-40% -$151K ﹤0.01% 2103
2025
Q4 		$444K Sell
17,668
-21,375
-55% -$502K ﹤0.01% 1945
2025
Q3 		$884K Buy
39,043
+18,102
+86% +$422K ﹤0.01% 1445
2025
Q2 		$362K Sell
20,941
-821
-4% -$15.2K ﹤0.01% 1744
2025
Q1 		$476K Buy
21,762
+9,129
+72% +$252K ﹤0.01% 1500
2024
Q4 		$403K Buy
+12,633
New +$380K ﹤0.01% 1572

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mercer Global Advisors's APLS Position: Q2 2026 in Review

Mercer Global Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 10,663 shares — an estimated $429K sold.

Mercer Global Advisors first reported a position in APLS in Q4 2024 and held it in 6 quarters. The position peaked at $884K in Q3 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Mercer Global Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Mercer Global Advisors sold 10,663 Apellis Pharmaceuticals shares in Q2 2026, an estimated $429K.
  • Mercer Global Advisors first reported a position in Apellis Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Mercer Global Advisors's Apellis Pharmaceuticals position peaked at $884K in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.